Ayşe Ünal Yüksekgönül
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ayşe Ünal Yüksekgönül has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Hazım Alper Gürsu
University of Health Sciences, Ankara Bilkent City Hospital
2 shared publications Tevfik Karagöz
Hacettepe University Faculty of Medicine, Department of Child Health and Diseases, Unit of Cardiology, Ankara, Turkey
2 shared publications- Ahmet Kuddusi İrDem
Department of Pediatric Cardiovascular Surgery, Ankara Bilkent City Hospital, Ankara, Türkiye
1 shared publication Akçahan Akalın
Hacettepe University Faculty of Medicine, Department of Child Health and Diseases, Unit of Genetics, Ankara, Turkey
1 shared publication- Benan Bayrakci
Department of Pediatric Critical Care Medicine, Life Support Practice and Research Center, Hacettepe University Faculty of Medicine, Ankara, Turkiye
1 shared publication - Bihter Karabacak
Ankara Bilkent City Hospital, Department of Pediatric Cardiology
1 shared publication
Latest Publications
- Open Access
- 13 November 2026
- Published by Harran Universitesi Tip Fakultesi Dergisi in Harran Üniversitesi Tıp Fakültesi Dergisi
- No. Advanced O
Can Thyroid Functions Be a Predictive Factor in Patients with Bronchopulmonary Dysplasia? A Single-Center Case-Control Study
Objective: Bronchopulmonary dysplasia (BPD) is a common pulmonary complication in preterm infants. Despite advances in neonatal care and improved survival rates, BPD remains a major cause of morbidity. This study aimed to evaluate the relationship between BPD and early thyroid function.Materials and Methods: This retrospective case-control study included infants with a gestational age of <37 weeks who were hospitalized for ≥28 days between January 2022 and December 2023. Demographic and clinical data, together with thyroid function tests (TFTs) obtained during the first weeks of life, were analyzed. Patients were divided into BPD and non-BPD groups for comparison.Results: A total of 172 infants were included, of whom 73 had BPD and 99 did not. Culture-proven sepsis (61.6% vs. 19.2%, p<0.001) and hemodynamically significant patent ductus arteriosus (hPDA) (37% vs. 6.1%, p<0.001) were more common in BPD patients. Thyroid-stimulating hormone (TSH) levels were significantly higher in the BPD group (8.66±17.34 vs. 3.41±2.13 mIU/L, p=0.001), whereas mean T4 levels were slightly lower (14.66±6.40 vs. 16.04±4.22 pmol/L), without statistical significance. Only three BPD patients were diagnosed with overt hypothyroidism.Conclusion: Although TSH levels was higher in BPD infants, most values remained within the normal range, and overt hypothyroidism was rare. These findings suggest that early alterations in TFT may reflect physiological adaptation rather than clinically significant thyroid dysfunction. Therefore, thyroid function parameters have limited utility as predictors of BPD. Further prospective, multicenter studies are needed to clarify this relationship.
- 13 November 2026
- Published by Harran Universitesi Tip Fakultesi Dergisi in Harran Üniversitesi Tıp Fakültesi Dergisi
- No. Advanced O
Open AccessCan Thyroid Functions Be a Predictive Factor in Patients with Bronchopulmonary Dysplasia? A Single-Center Case-Control Study
Objective: Bronchopulmonary dysplasia (BPD) is a common pulmonary complication in preterm infants. Despite advances in neonatal care and improved survival rates, BPD remains a major cause of morbidity. This study aimed to evaluate the relationship between BPD and early thyroid function.Materials and Methods: This retrospective case-control study included infants with a gestational age of <37 weeks who were hospitalized for ≥28 days between January 2022 and December 2023. Demographic and clinical data, together with thyroid function tests (TFTs) obtained during the first weeks of life, were analyzed. Patients were divided into BPD and non-BPD groups for comparison.Results: A total of 172 infants were included, of whom 73 had BPD and 99 did not. Culture-proven sepsis (61.6% vs. 19.2%, p<0.001) and hemodynamically significant patent ductus arteriosus (hPDA) (37% vs. 6.1%, p<0.001) were more common in BPD patients. Thyroid-stimulating hormone (TSH) levels were significantly higher in the BPD group (8.66±17.34 vs. 3.41±2.13 mIU/L, p=0.001), whereas mean T4 levels were slightly lower (14.66±6.40 vs. 16.04±4.22 pmol/L), without statistical significance. Only three BPD patients were diagnosed with overt hypothyroidism.Conclusion: Although TSH levels was higher in BPD infants, most values remained within the normal range, and overt hypothyroidism was rare. These findings suggest that early alterations in TFT may reflect physiological adaptation rather than clinically significant thyroid dysfunction. Therefore, thyroid function parameters have limited utility as predictors of BPD. Further prospective, multicenter studies are needed to clarify this relationship.
- 1 August 2026
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 36 (8) , 1745-1747
Incidentally diagnosed severe pulmonary valvar stenosis complicated by secondary cardiac hepatopathy in an adolescent: balloon valvoplasty as a bridge to surgery
Severe pulmonary valvar stenosis may remain silent into adolescence. A 17-year-old girl attended with vaginal bleeding; the diagnosis rested on a grade 6/6 murmur found on examination. Aminotransferases rose despite correction of anaemia and hypotension and fell only after balloon valvoplasty relieved the obstruction. The valve being dysplastic, valvoplasty was not curative, but it reversed the hepatic injury and allowed valve replacement to proceed safely.
- 1 August 2026
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 36 (8) , 1745-1747
Incidentally diagnosed severe pulmonary valvar stenosis complicated by secondary cardiac hepatopathy in an adolescent: balloon valvoplasty as a bridge to surgery
Severe pulmonary valvar stenosis may remain silent into adolescence. A 17-year-old girl attended with vaginal bleeding; the diagnosis rested on a grade 6/6 murmur found on examination. Aminotransferases rose despite correction of anaemia and hypotension and fell only after balloon valvoplasty relieved the obstruction. The valve being dysplastic, valvoplasty was not curative, but it reversed the hepatic injury and allowed valve replacement to proceed safely.
- Open Access
- 14 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (14) , 5499
Transcatheter Management of Congenital and Acquired Venous Lesions in Children
Background: Congenital and acquired venous abnormalities in children represent a heterogeneous group of conditions associated with significant clinical morbidity, including systemic desaturation, hepatic dysfunction, and life-threatening hemodynamic compromise. Evidence regarding transcatheter management across this diverse spectrum remains limited and largely confined to small, lesion-specific series. This study aimed to evaluate the feasibility, procedural, and clinical outcomes of transcatheter venous interventions in a heterogeneous pediatric population. Methods: This retrospective single-center study included all consecutive pediatric patients (median age: 9 years; range: 2 days–17 years) who underwent a total of 28 transcatheter procedures for congenital and acquired venous abnormalities between January 2022 and September 2025. Lesions included congenital portosystemic shunts (n = 4), systemic venous stenoses (n = 2), obstructed pulmonary venous pathways (n = 3), and veno-venous collaterals or azygos/hemiazygos continuation associated with Glenn circulation (n = 9). Procedural strategies were tailored according to anatomical characteristics, and outcomes were assessed in terms of technical success, procedural complications, and lesion-specific clinical and hemodynamic improvement. Results: A total of 28 transcatheter procedures were performed in 18 patients. The median procedure duration was 120 min (range, 35–235 min), and the median follow-up duration was 13.5 months (range, 0.6–35 months). During follow-up, two patients required reintervention for restenosis of previously treated lesions, whereas five additional procedures were performed because of newly developed veno-venous collaterals. Transcatheter interventions resulted in lesion-specific clinical and hemodynamic improvements, including reductions in serum ammonia levels, relief of venous obstruction, and improvements in oxygen saturation. One patient with complex pulmonary venous obstruction died following subsequent surgery despite initial hemodynamic improvement. Conclusions: In this single-center experience, transcatheter venous interventions were feasible and were associated with favorable immediate and mid-term clinical and hemodynamic outcomes in children with diverse venous abnormalities. Given the small sample size, heterogeneous patient population, and retrospective design, these findings should be considered preliminary. Larger prospective multicenter studies are warranted to better define optimal patient selection, timing of intervention, and long-term outcomes.
- 14 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (14) , 5499
Open AccessTranscatheter Management of Congenital and Acquired Venous Lesions in Children
Background: Congenital and acquired venous abnormalities in children represent a heterogeneous group of conditions associated with significant clinical morbidity, including systemic desaturation, hepatic dysfunction, and life-threatening hemodynamic compromise. Evidence regarding transcatheter management across this diverse spectrum remains limited and largely confined to small, lesion-specific series. This study aimed to evaluate the feasibility, procedural, and clinical outcomes of transcatheter venous interventions in a heterogeneous pediatric population. Methods: This retrospective single-center study included all consecutive pediatric patients (median age: 9 years; range: 2 days–17 years) who underwent a total of 28 transcatheter procedures for congenital and acquired venous abnormalities between January 2022 and September 2025. Lesions included congenital portosystemic shunts (n = 4), systemic venous stenoses (n = 2), obstructed pulmonary venous pathways (n = 3), and veno-venous collaterals or azygos/hemiazygos continuation associated with Glenn circulation (n = 9). Procedural strategies were tailored according to anatomical characteristics, and outcomes were assessed in terms of technical success, procedural complications, and lesion-specific clinical and hemodynamic improvement. Results: A total of 28 transcatheter procedures were performed in 18 patients. The median procedure duration was 120 min (range, 35–235 min), and the median follow-up duration was 13.5 months (range, 0.6–35 months). During follow-up, two patients required reintervention for restenosis of previously treated lesions, whereas five additional procedures were performed because of newly developed veno-venous collaterals. Transcatheter interventions resulted in lesion-specific clinical and hemodynamic improvements, including reductions in serum ammonia levels, relief of venous obstruction, and improvements in oxygen saturation. One patient with complex pulmonary venous obstruction died following subsequent surgery despite initial hemodynamic improvement. Conclusions: In this single-center experience, transcatheter venous interventions were feasible and were associated with favorable immediate and mid-term clinical and hemodynamic outcomes in children with diverse venous abnormalities. Given the small sample size, heterogeneous patient population, and retrospective design, these findings should be considered preliminary. Larger prospective multicenter studies are warranted to better define optimal patient selection, timing of intervention, and long-term outcomes.
- 4 October 2023
- Published by Galenos Yayinevi in Turkish Journal of Pediatric Emergency and Intensive Care Medicine
- Vol. 10 (3) , 216-220
Kawasaki Disease Shock Syndrome: Think Earlier, Treat Intensively
- 4 October 2023
- Published by Galenos Yayinevi in Turkish Journal of Pediatric Emergency and Intensive Care Medicine
- Vol. 10 (3) , 216-220
Kawasaki Disease Shock Syndrome: Think Earlier, Treat Intensively
- 14 April 2022
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 65 (6) , 104499
Efficacy of flecainide in bidirectional ventricular tachycardia and tachycardia-induced cardiomyopathy with Andersen-Tawil syndrome
- 14 April 2022
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 65 (6) , 104499
Efficacy of flecainide in bidirectional ventricular tachycardia and tachycardia-induced cardiomyopathy with Andersen-Tawil syndrome
- Open Access
- 1 December 2021
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 31 (12) , 2035-2037
Fluconazole-associated QT interval prolongation and Torsades de Pointes in a paediatric patient
"Torsades de pointes", a life-threatening rhythm disorder, is a polymorphic ventricular tachycardia that usually develops in association with a prolonged QT interval. Fluconazole, an anti-fungal drug, may also induce QT prolongation, in some cases subsequent torsades de pointes. Herein, we report a 16-year-old female presenting "torsades de pointes" after administration of fluconazole and rapidly improved upon cessation of the drug.
- 1 December 2021
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 31 (12) , 2035-2037
Open AccessFluconazole-associated QT interval prolongation and Torsades de Pointes in a paediatric patient
"Torsades de pointes", a life-threatening rhythm disorder, is a polymorphic ventricular tachycardia that usually develops in association with a prolonged QT interval. Fluconazole, an anti-fungal drug, may also induce QT prolongation, in some cases subsequent torsades de pointes. Herein, we report a 16-year-old female presenting "torsades de pointes" after administration of fluconazole and rapidly improved upon cessation of the drug.